Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1075115 Target Snapshot

Dual specificity tyrosine-phosphorylation-regulated kinase 4 · SINGLE PROTEIN · Homo sapiens

927Compounds
92Assays
1Approved Drugs
872.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9NR20. Use UniProt Q9NR20 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9NR20 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dual specificity tyrosine-phosphorylation-regulated kinase 4 as ChEMBL target CHEMBL1075115, mapped to UniProt Q9NR20. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dual specificity tyrosine-phosphorylation-regulated kinase 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1075115
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9NR20
Dual specificity tyrosine-phosphorylation-regulated kinase 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Dual specificity tyrosine-phosphorylation-regulated kinase 4 is the right protein anchor across sources, using UniProt Q9NR20 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDual specificity tyrosine-phosphorylation-regulated kinase 4
UniProt AccessionQ9NR20
Component TypeProtein
Sequence Length520 aa

Dual specificity tyrosine-phosphorylation-regulated kinase 4

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Dual specificity tyrosine-phosphorylation-regulated kinase 4, mapped to UniProt Q9NR20. Sequence length is 520 aa.

Mapped IDQ9NR20
Review nameDual specificity tyrosine-phosphorylation-regulated kinase 4
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase III
2
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC50324.0
KI548.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4784318 8.7 IC50 2.0 Preclinical
CHEMBL1965660 8.0 Ki 10.0 Preclinical
CHEMBL1981079 7.9 Ki 12.59 Preclinical
CHEMBL4873449 7.57 IC50 26.8 Preclinical
CHEMBL5400230 7.48 IC50 33.0 Preclinical
CHEMBL3103192 7.4 IC50 40.0 Preclinical
CHEMBL1978448 7.4 Ki 39.81 Preclinical
CHEMBL5438158 7.33 IC50 47.0 Preclinical
CHEMBL5405059 7.32 IC50 48.0 Preclinical
CHEMBL1964290 7.3 Ki 50.12 Preclinical
Distribution

pChEMBL Value Distribution

66
5.0
111
5.5
92
6.0
46
6.5
9
7.0
2
7.5
2
8.0
1
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

92
Total Assays
235
Tested Compounds
2
Assay Types
Binding — 91 assays, 235 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 78 209 6.0
assay format 10 2 5.1
cell-based format 3 24 5.8
Functional — 1 assays, 88 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 88 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine